2020-12372. Issuance of an Experimental Use Permit  

  • Start Preamble

    AGENCY:

    Environmental Protection Agency (EPA).

    ACTION:

    Notice.

    SUMMARY:

    EPA has granted an experimental use permit (EUP) to Oxitec, Ltd to test efficacy of OX5034 Aedes aegypti mosquitoes expressing tetracycline Trans-Activator Variant (tTAV-OX5034) protein for control of wild Aedes aegypti mosquitoes. An EUP permits use of a pesticide for experimental or research purposes only in accordance with the limitations in the permit.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Robert McNally, Biopesticides and Pollution Prevention Division (7511P), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; main telephone number: (703) 305-7090; email address: BPPDFRNotices@epa.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    I. General Information

    A. Does this action Apply to me?

    This action is directed to the public in general. Although this action may be of particular interest to those persons who conduct or sponsor research on pesticides, the Agency has not attempted to describe all the specific entities that may be affected by this action.

    B. How can I get copies of this document and other related information?

    The docket for this action, identified by docket identification (ID) number EPA-HQ-OPP-2019-0274, is available at http://www.regulations.gov or at the Office of Pesticide Programs Regulatory Public Docket (OPP Docket) in the Environmental Protection Agency Docket Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334, 1301 Constitution Ave. NW, Washington, DC 20460-0001. The Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566-1744, and the telephone number for the OPP Docket is (703) 305-5805.

    Please note that due to the public health emergency the EPA Docket Center (EPA/DC) and Reading Room was closed to public visitors on March 31, 2020. Our EPA/DC staff will continue to provide customer service via email, phone, and webform. For further information on EPA/DC services, docket contact information and the current status of the EPA/DC and Reading Room, please visit https://www.epa.gov/​dockets.

    II. EUP

    EPA has issued the following EUP:

    93167-EUP-2. Issuance. Oxitec, Ltd., c/o Wiley Rein 1776 K Street NW, Washington, DC 20006. This EUP allows the use of 0.0115 pounds (5193.56 mg) of the insecticide active ingredient tTAV-OX5034 protein on 6,600 acres to evaluate the control of Aedes aegypti mosquitoes. The program is authorized only in the States of Florida and Texas. The EUP is effective from April 30, 2020 to April 30, 2022.

    Start Authority

    Authority: 7 U.S.C. 136 et seq.

    End Authority Start Signature

    Dated: May 27, 2020.

    Robert McNally,

    Director, Biopesticides and Pollution Prevention Division, Office of Pesticide Programs.

    End Signature End Supplemental Information

    [FR Doc. 2020-12372 Filed 6-8-20; 8:45 am]

    BILLING CODE 6560-50-P

Document Information

Published:
06/09/2020
Department:
Environmental Protection Agency
Entry Type:
Notice
Action:
Notice.
Document Number:
2020-12372
Pages:
35307-35307 (1 pages)
Docket Numbers:
EPA-HQ-OPP-2019-0274, FRL-10010-07
PDF File:
2020-12372.pdf
Supporting Documents:
» Description of 2021 Expansion Amendment to OX5034 Aedes aegypti Mosquito, including Active and Inert Ingredients
» Application: Pesticide Experimental Use Permit
» Review of the Zhao et al., 2020 study on “Genetic Breakdown of a Tet-off Conditional Lethality System for Insect Population Control” and its Relevance to the OX5034 Ae. Aegypti Experimental Use Permit; EPA File Symbol 93167-EUP-1
» Letter regards to Meeting with EPA on November 12, 2020 Regarding the Oxitec Experimental Use Permit Approved on April 30, 2020
» Experimental Use Permit
» Human Health and Environmental Risk Assessment for the New Product OX5034 Containing the Tetracycline-Repressible Transactivator Protein Variant (tTAV-OX5034;New Active Ingredient) Protein, a DsRed2 Protein Variant (DsRed2-OX5034; New Inert Ingredient), and the Genetic Material (Vector pOX5034) Necessary for Their Production in OX5034 Aedes aegypti
» Section G OX5034 Aedes aegypti: Proposed Field Trial Protocol for an Experimental Use Permit
» OX5034 Aedes aegypti Species-specific Larvicide Effective in Killing Female Aedes aegypti Mosquito Larvae Label
» Review of Section G for an Experimental Use Permit 93167-EUP-E to Test OX5034 Aedes aegypti Mosquitoes Decision #549240
» Response to Comments OX5034 to the Notice of Receipt of an Application for an Experimental Use Permit Number 93167-EUP-E